New therapies for hepatitis C

被引：22

作者：

Modi, Apurva A. ^{[1
]}

Hoofnagle, Jay H. ^{[1
]}

机构：

[1] NIDDK, Liver Dis Branch, NIH, Bethesda, MD 20892 USA

来源：

HEPATOLOGY | 2007年 / 46卷 / 03期

关键词：

D O I：

10.1002/hep.21892

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

收藏

页码：615 / 617

页数：3

相关论文

共 22 条

[11] In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061 - Structural analysis indicates different resistance mechanisms [J].

Lin, C ;

Lin, K ;

Luong, YP ;

Rao, BG ;

Wei, YY ;

Brennan, DL ;

Fulghum, JR ;

Hsiao, HM ;

Ma, S ;

Maxwell, JP ;

Cottrell, KM ;

Perni, RB ;

Gates, CA ;

Kwong, AD .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (17) :17508-17514

[12]

Lin C., 2006, Infectious Disorders - Drug Targets, V6, P3, DOI 10.2174/187152606776056706

[13] Combination of a hepatitis C virus NS3-NS4A protease inhibitor and alpha interferon synergistically inhibits viral RNA, replication and facilitates viral RNA clearance in replicon cells [J].

Lin, K ;

Kwong, AD ;

Lin, C .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (12) :4784-4792

[14] High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C [J].

Lindahl, K ;

Stahle, L ;

Bruchfeld, A ;

Schvarcz, R .

HEPATOLOGY, 2005, 41 (02) :275-279

[15] Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial [J].

Manns, MP ;

McHutchison, JG ;

Gordon, SC ;

Rustgi, VK ;

Shiffman, M ;

Reindollar, R ;

Goodman, ZD ;

Koury, K ;

Ling, MH ;

Albrecht, JK .

LANCET, 2001, 358 (9286) :958-965

[16] The safety and efficacy of taribavirin plus pegylated interferon alfa-2a versus ribavirin plus pegylated interferon alfa-2a in therapy-naive patients infected with hcv: Phase 3 results [J].

Marcellin, P. ;

Lurie, Y. ;

Rodrigues-Torres, M. ;

Chasen, R. ;

Xu, Y. ;

Murphy, B. .

JOURNAL OF HEPATOLOGY, 2007, 46 :S7-S7

[17] The face of future hepatitis C antiviral drug development: Recent biological and virologic advances and their translation to drug development and clinical practice [J].

McHutchison, JG ;

Bartenschlager, R ;

Patel, K ;

Pawlotsky, JM .

JOURNAL OF HEPATOLOGY, 2006, 44 (02) :411-421

[18]

MCHUTCHISON JG, RESULTS INTERIM ANAL

[19]

Novozhenov V, 2007, GASTROENTEROLOGY, V132, pA778

[20] Synthesis and pharmacokinetics of valopicitabine (NM283), an efficient prodrug of the potent anti-HCV agent 2′-C-methylcytidine [J].

Pierra, Claire ;

Amador, Agnes ;

Benzaria, Samira ;

Cretton-Scott, Erika ;

D'Amours, Marc ;

Mao, John ;

Mathieu, Steven ;

Moussa, Adel ;

Bridges, Edward G. ;

Standring, David N. ;

Sommadossi, Jean-Pierre ;

Storer, Richard ;

Gosselin, Gilles .

JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (22) :6614-6620